Last update 01 Nov 2024
NIBEC Co., Ltd.
Last update 01 Nov 2024
Overview
Basic Info
Introduction Founded on February 20, 2004, NIBEC is headquartered in Jincheon-gun, South Korea. The company's diverse portfolio underscores its commitment to advancing medical products across different domains.
NIBEC Co., Ltd. is actively involved in the development, manufacturing, and commercialization of medical products and supplies. The company operates in various business areas, including oral care products, bio materials for tissue regeneration, cosmetics, and bio fusion peptide businesses.
In the Oral Care Products business, NIBEC offers a range of products such as tooth whitening, tooth desensitizer, and dental conditioner. The Bio Materials for Tissue Regeneration business focuses on providing bone graft materials, barriers, intraoral products, resorbable collagen membrane matrix, and growth-factor enhanced matrix. The Bio Fusion Peptide business is engaged in offering bone graft material, biodegradable collagen matrix, and synthetic bone graft material. |
Tags
Skin and Musculoskeletal Diseases
Neoplasms
Digestive System Disorders
Synthetic peptide
Recombinant polypeptide
Antibody
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
International Multicenter Post Market Clinical Follow-up research for OCS-B® and Regenomer® in Socket Preservation, a randomized, controlled clinical trial.
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase 1 Clinical Study To Evaluate The Pharmacokinetic Characteristics, Safety, And Tolerability After Subcutaneous Administration Of Np-201 Acetate Injection In Healthy Adult Volunteers
100 Clinical Results associated with NIBEC Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with NIBEC Co., Ltd.
Login to view more data
100 Translational Medicine associated with NIBEC Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 25 Dec 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
4
1
Phase 1 Clinical
Other
1
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free